Drug-tolerant persister (DTP) cell populations were originally discovered in antibiotic-
resistant bacterial biofilms. Similar populations with comparable features have since been …

The emergence of drug resistance is the most substantial challenge to the effectiveness of
anticancer therapies. Orthogonal approaches have revealed that a subset of cells, known as …

In colorectal cancers, the tumor microenvironment plays a key role in prognosis and therapy
efficacy. Patient-derived tumor organoids (PDTO) show enormous potential for preclinical …

Resistance to chemotherapy has been a major hurdle that limits therapeutic benefits for
many types of cancer. Here we systematically identify genetic drivers underlying …

Disease relapse driven by acquired drug resistance limits the effectiveness of most systemic
anti-cancer agents. Targeting persistent cancer cells in residual disease before relapse has …

Organoids are established through in vitro 3D culture, and they can mimic the structure and
physiological functions of organs or tissues in vivo. Organoids have attracted much attention …

In recent years, progress in nanotechnology provided new tools to treat cancer more
effectively. Advances in biomaterials tailored for drug delivery have the potential to …

Damage-associated molecular patterns (DAMPs) are endogenous molecules released by
cells in response to injury or stress, recognized by host pattern recognition receptors that …

Tissue regeneration after damage is generally thought to involve the mobilization of adult
stem cells that divide and differentiate into progressively specialized progeny. However …

Polyamines–putrescine, spermidine, and spermine–are widely distributed aliphatic
compounds known to regulate important biological processes in prokaryotic and eukaryotic …